{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:54:04Z","timestamp":1792547644067,"version":"4.5.0"},"reference-count":15,"publisher":"Oceanside Publications Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"Background:<\/jats:bold> Most patients with allergic rhinitis\/conjunctivitis (AR\/C) are sensitized to more than one allergen. An ongoing question is the efficacy of single-allergen immunotherapy in patients who are polysensitized. Objective:<\/jats:bold> To evaluate the efficacy\n and safety of grass, ragweed, tree, and house-dust mite (HDM) sublingual immunotherapy (SLIT) tablets in adults with AR\/C who are mono- or polysensitized. Methods:<\/jats:bold> Data from adults (ages \u2265 18 years) with AR\/C who participated in phase III double-blind, placebo controlled\n field trials (four grass, two ragweed, two HDM, one tree) were included in the post hoc<\/jats:italic> analyses. Efficacy was assessed by the total combined score (TCS) (sum of AR\/C daily symptom and medication scores) during the entire pollen season for grass and tree trials, and peak pollen season\n for ragweed trials versus placebo. Efficacy for the HDM SLIT-tablet was assessed by the total combined rhinitis score (TCRS) (sum of rhinitis daily symptom and medication scores) during the last 8 weeks of treatment versus placebo. Results:<\/jats:bold> For the grass SLIT-tablet, TCS\n improved by 20% (mean difference 1.33 [95% confidence interval {CI}, 0.44\u20102.22]) in the subjects who were monosensitized (n = 442) and 20% (mean difference 1.28 [95% CI, 0.90\u20101.67]) in the subjects who were polysensitized (n = 1857). For the ragweed SLIT-tablet, TCS improved\n by 19% (mean difference 1.72 [95% CI, \u22120.20 to 3.63]) in the subjects who were monosensitized (n = 115) and 27% (mean difference 2.27 [95% CI, 1.28\u20103.27]) in the subjects who were polysensitized (n = 528). For the tree SLIT-tablet, TCS improved by 54% (mean difference 4.65 [95%\n CI, 2.48\u20106.82]) in the subjects who were monosensitized (n = 138) and 34% (mean difference 2.51 [95% CI, 1.34\u20103.69]) in the subjects who were polysensitized (n = 437). For the HDM SLIT-tablet, TCRS improved by 20% (mean difference 1.24 [95% CI, 0.48\u20101.99]) in the subjects\n who were monosensitized (n = 468) and 17% (mean difference 0.85 [95% CI, 0.43\u20101.28]) in the subjects who were polysensitized (n = 1294). The overall safety profile was not qualitatively different between the subjects who were monosensitized and the subjects who were polysensitized.\n Conclusion:<\/jats:bold> Grass, ragweed, tree, or HDM SLIT-tablet treatment is effective for the specific allergen in question in adults with AR\/C and who are monosensitized or polysensitized. Targeting one relevant allergen with SLIT-tablets induces a clinical effect for that allergen\n in patients who were polysensitized.<\/jats:p>","DOI":"10.2500\/aap.2024.45.230068","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T04:39:42Z","timestamp":1703738382000},"page":"33-36","source":"Crossref","is-referenced-by-count":9,"title":["Sublingual immunotherapy tablets in monosensitized and polysensitized adults with allergic rhinoconjunctivitis"],"prefix":"10.2500","volume":"45","author":[{"given":"Harold S.","family":"Nelson","sequence":"first","affiliation":[{"name":"From the Department of Medicine, National Jewish Health, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David. I.","family":"Bernstein","sequence":"additional","affiliation":[{"name":"Division of Immunology and Allergy, University of Cincinnati College of Medicine and Bernstein Clinical Research Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilo","family":"Biedermann","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, Technical University of Munich, Munich, Germany, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Nolte","sequence":"additional","affiliation":[{"name":"ALK, Bedminster, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.jaci.2010.12.1106","article-title":"Allergy-related outcomes in relation to serum IgE: results from the National Health and Nutrition Examination Survey 2005-2006","volume":"127","author":"Salo","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/alr.21890","article-title":"Correlation between the number of allergen sensitizations and immunoglobulin E: monosensitization vs polysensitization","volume":"7","author":"Kuperstock","year":"2017","journal-title":"Int Forum Allergy Rhinol"},{"key":"B3","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/j.ejim.2011.05.009","article-title":"Monosensitization and polysensitization in allergic rhinitis","volume":"22","author":"Ciprandi","year":"2011","journal-title":"Eur J Intern Med"},{"key":"B4","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/all.12074","article-title":"Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects","volume":"68","author":"Nelson","year":"2013","journal-title":"Allergy"},{"key":"B5","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jaci.2018.12.1001","article-title":"The SQ tree SLIT-tablet is highly effective and well tolerated: results from a randomized, double-blind, placebo-controlled phase III trial","volume":"143","author":"Biedermann","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.jaci.2013.03.019","article-title":"Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults","volume":"131","author":"Creticos","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jaci.2006.05.003","article-title":"Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis","volume":"118","author":"Dahl","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jaci.2015.06.036","article-title":"Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized double-blind, placebo-controlled phase III trial","volume":"137","author":"Demoly","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.anai.2013.11.018","article-title":"Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial","volume":"112","author":"Maloney","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1477-5751-12-10","article-title":"A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma","volume":"12","author":"Murphy","year":"2013","journal-title":"J Negat Results Biomed"},{"key":"B11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaci.2010.11.035","article-title":"Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults","volume":"127","author":"Nelson","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.jaci.2016.06.044","article-title":"Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial","volume":"138","author":"Nolte","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.anai.2013.03.013","article-title":"Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults","volume":"110","author":"Nolte","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13223-016-0119-z","article-title":"Severity and disease control before house dust mite immunotherapy initiation: ANTARES a French observational survey","volume":"12","author":"Demoly","year":"2016","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4193\/Rhino14.282","article-title":"Real-life study showing better control of allergic rhinitis by immunotherapy than regular pharmacotherapy","volume":"54","author":"Droessaert","year":"2016","journal-title":"Rhinology"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2024\/00000045\/00000001\/art00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T04:41:04Z","timestamp":1703738464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2024.45.230068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,1]]}},"alternative-id":["1088-5412(20240101)45:1L.33;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2024.45.230068","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,1]]}}}